OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency https://lnkd.in/gpVmpkc
About us
At OPKO Health, we seek to serve unmet patient needs through our first in class products, comprehensive diagnostics laboratories, robust research and development pipeline, and unique pharmaceutical business solutions. The entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs. We are proud of our first in class products, Rayaldee® (calcifediol), and the 4Kscore® test, as well as our diagnostics division, BioReference Laboratories and GeneDx. In addition to our clinical products and diagnostics, we have a robust research and development pipeline and a variety of biomedical and pharmaceutical business solutions. Since our founding in 2007, OPKO has grown into a global healthcare company, with over 5500 employees spanning nine countries, through organic growth and complementary acquisitions. More information available at www.opko.com.
- Website
-
http://www.opko.com
External link for OPKO Health, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Miami, FL
- Type
- Public Company
- Founded
- 2007
- Specialties
- Pharmaceutical and Diagnostic Products, Medical Devices, and life sciences
Locations
-
Primary
Get directions
4400 Biscayne Blvd.
Miami, FL 33137, US
Employees at OPKO Health, Inc.
-
Donna Bell
-
Amy Bender
Presidents Club Award Winning Professional | Oncology | Nephrology | Rare Disease | Neurology | Specialty Sales Representative
-
Michelle Arden de la Rosa
Sr. Specialty Pharmaceutical Rep & People Leader
-
Luis "Louie" Paredes, PMP
OPKO Health, Renal Division: Director, Project Management, Includes Operations and Supply Chain